

MAR 12 2021

SENATE CONCURRENT RESOLUTION

REQUESTING THE DEPARTMENT OF HEALTH TO CONVENE A MEDICINAL
PSILOCYBIN AND PSILOCIN WORKING GROUP TO EXAMINE THE
MEDICINAL AND THERAPEUTIC EFFECTS OF PSILOCYBIN AND
PSILOCIN AND DEVELOP A LONG-TERM STRATEGIC PLAN TO ENSURE
THE AVAILABILITY OF MEDICINAL PSILOCYBIN AND PSILOCIN OR
PSILOCYBIN-BASED AND PSILOCIN-BASED PRODUCTS THAT ARE SAFE,
ACCESSIBLE, AND AFFORDABLE FOR ELIGIBLE ADULT PATIENTS.

1 WHEREAS, mental health conditions are treated in various
2 ways depending on the condition and can include medication,
3 therapy, and psychosocial services; and
4

5 WHEREAS, these treatments, while effective for certain
6 conditions and patients, do not treat all mental health
7 conditions; and
8

9 WHEREAS, psilocybin and psilocin occur naturally in certain
10 species of mushrooms; and
11

12 WHEREAS, psilocybin and psilocin are natural chemicals that
13 can activate serotonin receptors in the brain; and
14

15 WHEREAS, studies conducted by nationally and
16 internationally recognized medical institutions indicate that
17 psilocybin and psilocin have shown efficacy, tolerability, and
18 safety in the treatment of a variety of mental health
19 conditions, including addiction, depression, anxiety disorders,
20 and end-of-life psychological distress; and
21

22 WHEREAS, the United States Food and Drug Administration has
23 determined that preliminary clinical evidence indicates that
24 psilocybin and psilocin may demonstrate substantial improvement
25 over available therapies for major depressive disorder and
26 severe treatment-resistant depression and has granted a
27 breakthrough therapy designation for a treatment that uses
28 psilocybin and psilocin as a therapy for major depressive



1 disorder and a breakthrough therapy designation for a treatment
2 that uses psilocybin and psilocin as a therapy for severe
3 treatment-resistant depression; and
4

5 WHEREAS, Hawaii has a shortage of mental health
6 professionals and should actively consider novel, innovative,
7 and safe solutions to treat its citizens; now, therefore,
8

9 BE IT RESOLVED by the Senate of the Thirty-first
10 Legislature of the State of Hawaii, Regular Session of 2021, the
11 House of Representatives concurring, that the Department of
12 Health is requested to convene a Medicinal Psilocybin and
13 Psilocin Working Group, to be placed in the Department of Health
14 for administrative purposes; and
15

16 BE IT FURTHER RESOLVED that the Medicinal Psilocybin and
17 Psilocin Working Group is requested to examine:
18

- 19 (1) Federal, state, and local laws, regulations,
20 administrative rules, and procedures regarding the
21 medicinal use of psilocybin and psilocin;
22
- 23 (2) Available medical, psychological, and scientific
24 studies, research, and other information relating to
25 the safety and efficacy of psilocybin and psilocin in
26 treating mental health conditions; and
27
- 28 (3) Requirements, specifications, and guidelines for a
29 medical professional to prescribe and provide
30 psilocybin and psilocin to patients; and
31

32 BE IT FURTHER RESOLVED that the Medicinal Psilocybin and
33 Psilocin Working Group is requested to develop a long-term
34 strategic plan to ensure the availability of medicinal
35 psilocybin and psilocin or psilocybin-based and psilocin-based
36 products that are safe, accessible, and affordable for adults
37 twenty-one years of age or older; and
38

39 BE IT FURTHER RESOLVED that the following individuals, or
40 their respective designees, are requested to serve as members of
41 the Medicinal Psilocybin and Psilocin Working Group:
42



- (1) The Director of Health, who is requested to serve as chairperson of the working group;
- (2) The Attorney General;
- (3) The Dean of the John A. Burns School of Medicine at the University of Hawaii at Manoa;
- (4) The chairs of the Senate and House of Representatives standing committees whose subject matter purview is primarily responsible for reviewing legislation relating to health and to the Judiciary;
- (5) A physician duly licensed under Chapter 453, Hawaii Revised Statutes, or advanced practice registered nurse with the authority to prescribe psychotropic medication and duly licensed under Chapter 457, Hawaii Revised Statutes, to be invited by the chairperson of the working group;
- (6) A psychiatrist duly licensed under Chapter 453, Hawaii Revised Statutes, to be invited by the chairperson of the working group;
- (7) A representative of the Drug Policy Forum of Hawaii, to be invited by the chairperson of the working group;
- (8) A representative of the Clarity Project, to be invited by the chairperson of the working group;
- (9) A representative of the public with psychedelics-related industry experience, to be invited by the chairperson of the working group;
- (10) A representative of the Hawaii Psychological Association, to be to be invited by the chairperson of the working group;
- (11) A representative of the Hawaii Psychiatric Medical Association, to be invited by the chairperson of the working group; and



1 (12) A member of the public with executive or managerial
2 responsibilities for a medical cannabis dispensary
3 licensed under Chapter 329D, Hawaii Revised Statutes,
4 or a representative of the Hawaii Educational
5 Association for Licensed Therapeutic Healthcare, to be
6 appointed by the chairperson of the working group; and
7

8 BE IT FURTHER RESOLVED that the chairperson of the
9 Medicinal Psilocybin and Psilocin Working Group may invite other
10 interested parties with relevant experience to join the working
11 group; and
12

13 BE IT FURTHER RESOLVED that the Medicinal Psilocybin and
14 Psilocin Working Group is requested to submit a preliminary
15 report of its findings and recommendations to the Legislature no
16 later than twenty days prior to the convening of the Regular
17 Session of 2022, and a final report of its findings and
18 recommendations, including any proposed legislation, to the
19 Legislature no later than twenty days prior to the convening of
20 the Regular Session of 2023; and
21

22 BE IT FURTHER RESOLVED that the Medicinal Psilocybin and
23 Psilocin Working Group be dissolved on July 1, 2023; and
24

25 BE IT FURTHER RESOLVED that certified copies of this
26 Concurrent Resolution be transmitted to the Director of Health,
27 Attorney General, and Dean of the John A. Burns School of
28 Medicine.
29
30
31

OFFERED BY: 

